$MNPR News

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125

Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease

BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117

HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026.

Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Patients With Wilson Disease

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Reported Sunday, Monopar Presents Phase 3 Data At AAN 2026 Showing ALXN1840 Delivers Greater Neurologic Benefit And Lower Worsening Rates Versus Standard Of Care In Wilson Disease

Reported Sunday, Monopar Presents Phase 3 Data At AAN 2026 Showing ALXN1840 Delivers Greater Neurologic Benefit And Lower Worsening Rates Versus Standard Of Care In Wilson Disease

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update